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Accepted 29 June 2017In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015–16,
we conducted a multicentre test negative case control study in hospitals of 11 European countries to
measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among
people aged 65 years. We pooled four seasons data to measure IVE by past exposures to influenza vac-
cination.
We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute
respiratory infection 7 days before admission. Cases were patients RT-PCR positive for influenza virus
and controls those negative for any influenza virus. We documented seasonal vaccination status for
the current season and the two previous seasons.
We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B
case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current sea-
sonal IVE (pooled across seasons) was 30% (95%CI:35 to 64), 8% (95%CI: 94 to 56) and 33% (95%CI:43
to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both
previous seasons, current seasonal IVE (pooled across seasons) was 1% (95%CI: 80 to 43), 37% (95%CI:
7–57) and 43% (95%CI: 1–68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively.
Our results suggest that, regardless of patients’ recent vaccination history, current seasonal vaccine
conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and
B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective
against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort
studies documenting exposures to vaccine and natural infection is needed.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
The World Health Organization (WHO) strategy for seasonal
influenza vaccination aims at reducing death and hospitalisation
among individuals at risk of severe influenza [1]. In Europe, annual
vaccination is recommended to individuals with specific underlying
conditions and elderly [2]. Despite WHO recommendation to reach
75% coverage in elderly by 2010, uptake among Europeans aged
65 years and above was below 50% in 2014 [3]. Results of recent
studies question the effect of repeated influenza vaccinations on
influenza vaccine effectiveness (IVE) [4–7].
Immunologists suggest that past natural influenza infections
may enhance immune response to new variant influenza viruses
[8] and that genetic distances between consecutive vaccine compo-
nents and circulating strains may affect IVE [6]. Previous seasons’
vaccination may provide some residual protection but may also
modify current seasonal IVE [4,5,9]. The few epidemiological stud-
ies describing the effect of repeated vaccinations, have mainly
focused on primary care based studies with non-severe outcomes
[4,5,9,10]. Further understanding the role of repeated vaccinations
on seasonal IVE in elderly is important to better interpret current
seasonal IVE, guide new vaccine development and, eventually,
inform vaccination strategies [11].
We have set up two European networks of hospitals (InNHOVE
2011–14 & I-MOVE plus since 2015) allowing to measure seasonal
IVE against laboratory confirmed hospitalised influenza among
elderly [12–14]. The same generic protocol was used across seasons
[15,16].
We pooled four seasons data to measure, among patients aged
65 years and above, the IVE against hospitalisations associated with
influenza A(H3N2), A(H1N1)pdm09 and B infections according to
past exposures to influenza vaccination.2. Methods
We conducted a multicentre hospital-based case-control study
using the test-negative design (TND) [17]. We included between
three and twelve study sites per season in the analysis.The study population consisted of all community-dwelling indi-
viduals aged 65 years and above admitted as inpatients with influ-
enza related illness, and who had no contra-indication for influenza
vaccination or previous laboratory confirmed influenza in the
season.
We defined specific study periods for each influenza season,
study site and influenza (sub)type as lasting from the week of the
first to the week of the last laboratory confirmed case of a given
(sub)type of influenza.
We included hospitalised patients who had in the past seven
days at least one systemic (fever or feverishness, malaise, headache,
myalgia) and at least one respiratory symptoms (cough, sore throat
or shortness of breath).
In the participating services of each hospital, patients admitted
for clinical conditions that could be related to influenza were
screened for eligibility. The study teams swabbed patients meeting
the inclusion criteria. Specimens were tested by RT-PCR and
patients classified as influenza A(H1N1)pdm09, A(H3N2), B cases
or controls if their specimens tested negative for all influenza
viruses.
We documented seasonal vaccination status for the current sea-
son (defined as the season when the patients were included in the
study and therefore tested positive or negative for influenza) and
the two previous seasons. We defined patients as vaccinated if they
had been vaccinated at least 14 days before symptoms onset.
Otherwise, they were considered as unvaccinated.
Hospital study teams collected patients’ demographic character-
istics, date of current seasonal vaccination, underlying conditions
(diabetes mellitus, obesity, cardiovascular, lung diseases, and can-
cer), number of hospitalisations for underlying diseases in the past
12 months and smoking status. Underlying conditions were col-
lected through interviews with patients (or their relatives) and hos-
pital and/or primary care databases. In Finland, Spain (including
Valencia and Navarra) and Portugal, vaccination status was
retrieved from vaccination registers. In study sites with no vaccina-
tion register, study teams collected vaccination status for current
and past seasons through patients’ interview. For patients vacci-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4300 M. Rondy et al. / Vaccine 35 (2017) 4298–4306called patients’ GP or pharmacists or searched for vaccination
passes to retrieve vaccination status and date of uptake.
For each season, we pooled data from participating hospitals.
Using the odds ratio (OR) of being vaccinated between cases and
controls we computed the VE as (1 – OR) x 100%. We performed
a logistic regression to adjust IVE estimates for potential con-
founders. We used the one in ten rule of predictor degrees of free-
dom to events to determine the number covariates to include in
analyses with low sample sizes in order to avoid overfitting the
model [18,19]. We used a one-stage method with study site as a
fixed effect. Due to low sample and inherent risks for overfitting,
and based on previously published data [12–14], we apriori decided
on adjustment variables. When sample size allowed, we further
adjusted IVE estimates for month of symptoms onset, age (mod-
elled as a restricted cubic spline with four knots) and presence of
chronic conditions. We pooled data from seasons with circulation
of the same (sub)type specific influenza and computed pooled IVE
further adjusting on the season.
In a stratified analysis based on the data pooled across seasons
and using unvaccinated in the current season as a reference, we
compared VE measured in the current season between individuals
who were vaccinated in the past season and those who were not
vaccinated in the past season. Due to low sample size, we excluded
patients vaccinated in only one of the two previous seasons from
this analysis.
Using patients unvaccinated in current and the two previous
seasons as the reference, we conducted an indicator analysis. We
computed the effectiveness of being vaccinated in current season
only, in previous season but not current (regardless of penultimate
season vaccine status), and in current and both previous seasons for
each season and overall. Due to low sample size, we excluded
patients vaccinated in the penultimate season only, those vacci-
nated in the penultimate and current seasons only and those vacci-
nated in the previous and current seasons only.
We conducted sensitivity analyses restricted to patients for
whom the vaccination status ascertainment was based on vaccina-
tion registers.3. Results
We included 21 hospitals in 2011–12, 18 in 2012–13, 12 in
2013–14 and 25 in 2015–16. The 5295 patients recruited over the
four seasons included 465A(H1N1)pdm09, 642A(H3N2), 278 B
case-patients and 3910 controls (Table 2) for whom current vacci-
nation status was available. Previous vaccination information was
missing for 116 (8.2%) cases and 255 (6.5%) controls.
We included seasons 2012–13, 2013–14 and 2015–16 for A
(H1N1)pdm09 analyses, seasons 2011–12, 2012–13 and 2013–14
for A(H3N2) and seasons 2012–13 and 2015–16 for influenza B
analyses (Table 1).3.1. Influenza A(H1N1)pdm09
Vaccine and circulating A(H1N1)pdm09 viruses remained stable
across the study period (Table 1).
The median age was 76 years among A(H1N1)pdm09 cases and
79 years among controls (p < 0.01). A higher proportion of controls
than cases had respiratory chronic conditions (47% vs 40%, p < 0.01)
and were obese (21% vs 13%, p < 0.01). A higher proportion of A
(H1N1)pdm09 cases than controls had cancer (25% vs 18%,
p < 0.01) (Table 2).
Season specific IVE against A(H1N1)pdm09 virus ranged
between 15% (95%CI: 51 to 52) in 2012–13 and 41% (95%CI: 20–
57) in 2015–16. Pooled across 2012–13, 2013–14 and 2015–16,
IVE against A(H1N1)pdm09 virus was 38% (95%CI: 21–51) (Table 3).
Table 2
Characteristics for influenza A(H1N1)pdm09, A(H3N2) and influenza B, and controls included in the study, InNHOVE 2011–14 and I-MOVE + 2015–16.
A(H1N1)pdm09 A(H3N2) B
Cases Controls Cases Controls Cases Controls
(N = 465) % (N = 2462) % p-value (N = 642) % (N = 1798) % p-value (N = 278) % (N = 1996) % p-value
Median age 75.6 79.0 0.000 80.0 79.7 0.550 77.0 79.0 0.025
Sex = Male 0,557484 55.7 1353/2461 55.0 0.799 348/642 54.2 991/1798 55.1 0.712 136/278 48.9 1074/1995 53.8 0.140
Vaccine status
Current season influenza vaccination 196/465 42.2 1493/2462 60.6 0.000 385/642 60.0 1186/1798 66.0 0.007 130/278 46.8 1216/1996 60.9 0.000
Previous two and current season vaccination
None 200/423 47.3 669/2346 28.5 0.000 121/591 20.5 300/1671 18.0 0.332 95/255 37.3 556/1922 28.9 0.000
Current season only 15/423 3.5 95/2346 4.0 12/591 2.0 38/1671 2.3 9/255 3.5 78/1922 4.1
Current and previous seasons 12/423 2.8 101/2346 4.3 36/591 6.1 92/1671 5.5 8/255 3.1 69/1922 3.6
Current and penultimate seasons 8/423 1.9 80/2346 3.4 12/591 2.0 41/1671 2.5 1/255 0.4 63/1922 3.3
All three seasons 153/423 36.2 1170/2346 49.9 321/591 54.3 1004/1671 60.1 111/255 43.5 970/1922 50.5
Penultimate and previous seasons 18/423 4.3 135/2346 5.8 52/591 8.8 112/1671 6.7 20/255 7.8 110/1922 5.7
Previous season only 8/423 1.9 32/2346 1.4 17/591 2.9 37/1671 2.2 2/255 0.8 28/1922 1.5
Penultimate season only 9/423 2.1 64/2346 2.7 20/591 3.4 47/1671 2.8 9/255 3.5 48/1922 2.5
Unknown vaccination status 42 116 51 127 23 74
Presence of comorbidities
Diabetes 135/455 29.7 759/2431 31.2 0.544 211/637 33.1 578/1786 32.4 0.730 75/257 29.2 595/1963 30.3 0.773
Cardiac disease 266/461 57.7 1422/2451 58.0 0.918 322/640 50.3 966/1795 53.8 0.128 148/275 53.8 1174/1987 59.1 0.103
Respiratory diseases 185/461 40.1 1152/2448 47.1 0.007 294/641 45.9 844/1795 47.0 0.645 104/276 37.7 971/1977 49.1 0.000
Cancer 114/460 24.8 437/2449 17.8 0.001 116/289 40.1 327/1071 30.5 0.002 30/273 11.0 362/1982 18.3 0.003
Obesity 59/458 12.9 511/2421 21.1 0.000 134/638 21.0 442/1783 24.8 0.058 49/272 18.0 401/1962 20.4 0.376
Any chronic disease 425/460 92.4 2279/2462 92.6 0.923 549/642 85.5 1605/1797 89.3 0.012 237/278 85.3 1861/1996 93.2 0.000
More than one chronic condition 313/457 68.5 1741/2451 71.0 0.288 370/642 57.6 1148/1798 63.8 0.006 158/276 57.2 1417/1988 71.3 0.000
Hospitalisations in previous 12 months 196/455 43.1 1044/2446 42.7 0.877 206/640 32.2 691/1797 38.5 0.005 89/276 32.2 857/1969 43.5 0.000
Current smoking 108/449 24.1 357/2386 15.0 0.000 81/640 12.7 193/1793 10.8 0.191 49/270 18.1 319/1910 16.7 0.544
Antivirals treatment prior to swabbing 42/463 9.1 45/2457 1.8 0.000 9/631 1.4 16/1782 0.9 0.452 19/275 6.9 36/1993 1.8 0.000













Adjusted vaccine effectiveness against influenza A(H1N1)pdm09, A(H3N2) and B by season, among patients aged 65 years and older, InNHOVE 2011–14 and I-MOVE + 2015–16.*
Influenza type/subtype Season Number of hospitals N Cases Vaccinated cases Controls Vaccinated controls IVE 95%CI
A(H1N1)pdm09 Pooleda 2927 465 196 2462 1493 37.6 (20.6 to 50.9)
12–13b 18 1230 56 30 1174 755 15.1 (-51.2 to 52.3)
13–14c 12 382 56 28 326 204 34.1 (-22.2 to 64.5)
15–16d 25 1315 353 138 962 534 41.2 (20.3 to 56.7)
A(H3N2) Poolede 2440 642 385 1798 1186 28.9 (13.2 to 41.7)
11–12f 21 1438 473 301 965 654 13.6 (-11.9 to 33.3)
12–13g 18 417 44 17 373 252 62.5 (23.1 to 81.7)
13–14h 12 585 125 67 460 280 40.3 (7.9 to 61.3)
B Pooledi 2274 278 130 1996 1216 44.3 (26.2 to 58.0)
12–13j 18 1165 172 81 993 636 38.0 (11.1 to 56.8)
15–16k 25 1109 106 49 1003 580 50.5 (21.3 to 68.9)
List of study sites included in the analysis:
a ES FI FR HR IT LT NA NL PL PT RO VA.
b FR IT LT NA VA.
c FR NA.
d ES FI FR HR IT LT NA NL PL PT RO.
e FR IT LT NA VA.
f FR IT NA VA.
g FR IT LT NA VA.
h FR IT NA.
i ES FI FR HR HU IT LT NA NL PL PT RO VA.
j FR IT LT NA VA.
k ES FI FR HR HU IT LT NA NL PL PT RO.
* Adjusted for study site, date of onset, age, presence of at least one chronic condition and season.
Table 4
Influenza vaccine effectiveness for current season stratified by two previous seasons vaccination status by influenza (sub)type and season, InNHOVE, 2011–14 and I-MOVE
+ 2015–16.*
Type subtype Seasons included Among those not vaccinated in either of the two
previous seasons











A(H1N1)pdm091 2012–13, 2013–14 and 2015–16 212 (14) 764 (95) 30 (35 to 64) 171 (153) 1305 (1170) 1 (80 to 43)
A(H3N2)2 2011–12, 2012–13 and 2013–14 133 (12) 338 (38) 8 (94 to 56) 373 (321) 1116 (1004) 37 (7 to 57)
B3 2012–13 and 2015–16 104 (9) 634 (78) 33 (43 to 68) 131 (111) 1080 (970) 43 (1 to 68)
* Adjusted for study site, month of onset, age, presence of chronic conditions and season.
1 Missing vaccination status for 42 influenza A(H1N1)pdm09 cases and 116 controls. Missing information on chronic conditions for 3 influenza A(H1N1)pdm09 cases.
2 Missing vaccination status for 51 influenza A(H3N2) cases and 127 controls. Missing information on chronic conditions for 1 control.
3 Missing vaccination status for 23 influenza B cases and 74 controls.
4302 M. Rondy et al. / Vaccine 35 (2017) 4298–4306In the stratified analysis, current season IVE (pooled across sea-
sons) was 30% (95%CI: 35 to 64) among those not vaccinated in
either of the two previous seasons and 1% (95%CI: 80 to 43)
among those vaccinated in both previous two seasons (Table 4).
In the indicator analysis, using patients never vaccinated in the
three seasons as the reference, pooled season IVE when vaccinated
in the three seasons was 39% (95%CI: 19–54). Among those unvac-
cinated in the current season but vaccinated in the previous season,
IVE was 30% (95%CI: 8 to 55) (Table 5).3.2. Influenza A(H3N2)
Vaccine components, as recommended by WHO, were antigeni-
cally similar to circulating strains in all A(H3N2) seasons included
in this analysis (table 1). In 2012–13, mutations in the egg-
adapted A(H3N2) vaccine strain led to a vaccine strain antigenically
distinct from the circulating one [20].
A(H3N2) case-patients had the same median age (80 years,
p = 0.55) and sex ratio (p = 0.71) as their respective controls. A total
of 85% of cases and 89% of controls had at least one underlying con-
dition (p = 0.01) and 32% of cases and 38% of controls (p < 0.01) had
been hospitalised for chronic conditions in the past 12 months
(Table 2).Season specific IVE against A(H3N2) virus ranged between 14%
(95%CI: 12 to 33) in 2011–12 and 63% (95%CI: 23–82) in 2012–
13. Pooled across 2011–12, 2012–13 and 2013–14, IVE against A
(H3N2) virus was 29% (95%CI: 13–42) (Table 3).
In the stratified analysis, current season IVE (pooled across sea-
sons) was 8% (95%CI: 94 to 56) among those not vaccinated in
either of the two previous seasons and 37% (95%CI: 7–57) among
those vaccinated in both previous two seasons (Table 4).
In the indicator analysis, using patients never vaccinated in the
three seasons as the reference, pooled season IVE when vaccinated
in the three seasons was 39% (95%CI: 19–53). Among those
unvaccinated in the current season but vaccinated in the previous
season, IVE was 14% (95%CI: 23 to 40) overall. It was 25%
(95%CI: 22 to 53) in 2011–12 and 9% (95%CI: 80 to 54) in
2013–14 (Table 5).3.3. Influenza B
In 2012–13, vaccine and circulating lineages were Yamagata
while vaccines contained Victoria in the two previous seasons. In
2015–16, the current and two previous seasonal vaccines contained



















































































































































































































































































































































































































































































































































































































































































































































































































































M. Rondy et al. / Vaccine 35 (2017) 4298–4306 4303The median age was 77 years for Influenza B cases and 79 years
for controls (p = 0.02). A higher proportion of controls than cases
had respiratory chronic conditions (49% vs 38%, p < 0.01), cancer
(18% vs 11%, p < 0.01) and were hospitalised for chronic conditions
in the past twelve months (44% vs 32%, p < 0.01) (Table 2).
Season specific IVE against influenza B virus was 38% (95%CI:
11–57) in 2012–13 and 51% (95%CI: 21–69) in 2015–16. Pooled
across 2012–13 and 2015–16, IVE against B virus was 44% (95%
CI: 26–58) (table 3).
In the stratified analysis, current season IVE (pooled across sea-
sons) was 33% (95%CI: 43 to 68) among those not vaccinated in
either of the two previous seasons and 43% (95%CI: 1–68) among
those vaccinated in both previous two seasons (Table 4).
In the indicator analysis, using patients never vaccinated in the
three seasons as the reference, pooled season IVE when vaccinated
in the three seasons was 37% (95%CI: 12–54). Among those unvac-
cinated in the current season but vaccinated in the previous season,
IVE was 4% (95%CI: 66 to 35) overall; 31% (95%CI: 137 to 28)
in 2012–13 and 23% (95%CI: 76 to 66) in 2015–16 (Table 5).
In sensitivity analyses restricted to patients for whom vaccine
status was ascertained using registries, point estimates were close
to the original analysis point estimates in most instances. In the
indicator analysis, point estimates sometimes derived from the
original analysis but confidence intervals in both analyses largely
overlapped (Supplementary Tables 1 and 2).4. Discussion
Our results suggest that, regardless of patients’ recent vaccina-
tion history, current seasonal vaccine conferred protection to vacci-
nated patients against hospitalisation associated with influenza
infections in all instances except against A(H1N1)pdm09 among
patients vaccinated in both the previous two seasons. Taking as a
reference patients unvaccinated in the past two and the current
season, the highest IVE point estimate was systematically observed
among patients vaccinated in all three (current and two previous)
seasons.
As in previously published studies [5,9,13], we used patients
never vaccinated in three seasons as reference to measure the effect
conferred by various vaccination patterns in the three seasons. This
also allowed us to discuss the residual effect of previous vaccina-
tion, alone or combined with vaccination in the current season.
Using a stratified analysis with patients unvaccinated in the current
season as reference, we measured how much former vaccination
modified the effectiveness of current vaccination. This allowed us
to discuss the protection conferred by the current season vaccine,
provided recent vaccine history.
Limitations need to be discussed before further interpreting our
results.
High risk groups may be more likely to be vaccinated and to
develop a severe form of influenza, leading to chances for underes-
timation of IVE. In our study, adjustment on underlying chronic
conditions or hospitalisation for chronic conditions in the previous
year did not change the IVE estimates. However, unmeasured con-
founding cannot be excluded. Previous seasons’ vaccination status
was missing for less than 10% of patients. Vaccination status ascer-
tainment relied on patients’ and physicians’ interviews for 32% of
recruited patients; otherwise vaccination status was ascertained
based on vaccine registries. Recall bias on vaccination status (previ-
ous and current vaccinations) could affect IVE estimates if differen-
tial between cases and controls. We believe that differential recall
bias is not present in our study as vaccination status was collected
independently from the patients’ laboratory results. Furthermore,
the results were similar when restricting to patients with vaccina-
tion status extracted from vaccination registers.
4304 M. Rondy et al. / Vaccine 35 (2017) 4298–4306The literature suggests that elderly have consistent vaccination
habits over time. Having been vaccinated in the past seasons was
reported as a strong predictor of current vaccination status [21–
23]. This led, in our study, to small number of patients with chang-
ing vaccination status. Despite pooling seasons we still had low
precision estimates of current IVE according to past seasons vacci-
nation. We cannot exclude that the observed differences are due to
random errors. Due to small sample size, we could not interpret
season specific results. The role of previous vaccination on current
IVE may vary by season as genetic distance between previous and
current vaccine strains as well as with the circulating strains
change. Prior vaccination may negatively interfere with current
vaccine when antigenic distance between vaccine and circulating
strains is large but distance between consecutive vaccine compo-
nents is small [6]. Enlarging the number of participating hospitals
will allowmeasuring seasonal effect of previous vaccination on cur-
rent IVE with more precise estimates.
Our study population was elderly population in the EU. They are
offered annual vaccination for free [24] and have a higher probabil-
ity than younger adults of having been exposed to influenza viruses
in the past. Effects of previous vaccination and/or infection on IVE
may be of different magnitude according to birth cohorts. Epidemi-
ological inputs into these theories would require setting up longitu-
dinal studies with prospective collection of vaccination status and
natural infection.
Keeping in mind the above limitations, our results suggest some
residual effects from previous year vaccination against A(H1N1)
pdm09 virus, a very limited effect against A(H3N2) virus and no
effect against influenza B virus. Residual protection against A
(H1N1)pdm09 virus was previously suggested [25] and may be
explained by some antigenic stability of A(H1N1)pdm09 viruses
over time [26]. These results are also consistent with findings sug-
gesting stable within-season IVE against A(H1N1)pdm09 [27] and
decreasing IVE against A(H3N2) and B viruses. On the other hand,
recent findings from McLean et al. measuring IVE against primary
health care endpoints among adults suggested some residual pro-
tections against influenza A(H3N2) and B viruses [9]. Diminished
immune response to influenza vaccination in elderly compared
with younger age group [28] could lead to shorter duration of pro-
tection among older adults and explain the discrepancy between
McLean’s and our results. The small number of seasons included
in this analysis may also explain differences observed with McLean
et al. We included only two influenza B seasons with different pat-
terns in terms of consecutive circulating and vaccine lineages and
we could rely only on surveillance data to interpret lineages circu-
lation. Lineage characterisation at the individual level would ease
the interpretation of our results. Understanding previous effect of
seasonal vaccination against influenza B may help vaccine lineage
selection. Among possible lineage selection strategies, the yearly
alternative approach proposes to alternate one Yamagata and one
Victoria strain, assuming a one-year residual protection against
the other lineage [31].
Stratified analyses suggested some interference from previous
vaccinations on current season IVE against A(H1N1)pdm09 (nega-
tive effect) and against A(H3N2) (positive effect) but very limited
effect against influenza B viruses. We observed that current season
IVE against A(H1N1)pdm09 viruses was close to null among
patients vaccinated in both previous two seasons and 30% among
patients not vaccinated in either of the two previous seasons. This
observation, potentially explained by residual protection from pre-
vious vaccination, is in line with a recently published study con-
cluding that current influenza vaccination or several prior doses
are needed to have a high protective effect against A(H1N1)
pdm09 viruses [32]. Despite largely overlapping confidence inter-
vals, our stratified analysis suggested that patients previously vac-
cinated had a higher current seasonal IVE (37% when vaccinated inboth previous seasons) against A(H3N2) viruses compared with
patients unvaccinated in the previous seasons (8%). Although anti-
body titers are poor surrogates for vaccine protection [33], such
positive effect has been previously suggested for A(H3N2) viruses
based on comparison of sero-responses to different vaccination pat-
terns [34]. Most studies measuring VE against medically-attended
influenza A(H3N2) in adults reported negative effect of repeated
vaccination against A(H3N2) viruses. Authors of these studies
hypothesised that this negative effect could be due to either the
original antigenic sin [9,35] or antigenic distance hypothesis [5].
None of the A(H3N2) seasons included in our analysis met the cri-
teria to fulfill the antigenic distance hypothesis. Furthermore, these
differences between our results and published studies may reflect
random errors due to small numbers or differences in the outcomes
and study populations.
5. Conclusion
To our knowledge, this work is the largest hospital based IVE
study presenting the effects of repeated vaccination. Our results
suggest that, regardless of patients’ recent vaccination history, cur-
rent seasonal vaccine conferred protection to vaccinated patients
against hospitalised influenza in all instances except against A
(H1N1)pdm09 viruses among patients vaccinated in the past two
seasons. Meanwhile, working on a different, long lasting and more
efficient influenza vaccine is urgent. Engaging in longitudinal stud-
ies, prospectively collecting exposure to both influenza vaccination
and influenza infection, is needed to understand potential interfer-
ences between consecutive vaccinations. Acquiring such knowl-
edge is crucial at a time when universal influenza vaccination is
being recommended in an increasing number of countries.
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